GKOS - iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product Surpassing Market Expectations Says Analyst | Benzinga
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
William Blair suggests that the approval paves the way for what they anticipate to be the company's most successful product to date, poised to revolutionize the treatment of glaucoma by addressing issues related to noncompliance with drops.
Glaukos has set a wholesale acquisition cost of $13,950 per dose (or implant) for ...